A new research document with title ‘Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2017’ covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Allergan Plc, AnaMar AB, Angion Biomedica Corp …………….The report will help user gain market insights, future trends and growth prospects for Review, H2 2017
The latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.
Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.
Request a sample report @ https://www.htfmarketreport.com/sample-report/593315-systemic-sclerosis-5
The Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
– The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=593315
Companies Mentioned in the Report
Angion Biomedica Corp
arGentis Pharmaceuticals LLC
BLR Bio LLC
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Covis Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc
- Hoffmann-La Roche Ltd
Fibrocell Science Inc
Gilead Sciences Inc
Leadiant Biosciences Inc
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
ProMetic Life Sciences Inc
Seattle Genetics Inc
Stemline Therapeutics Inc
Vicore Pharma AB
viDA Therapeutics Inc
VivaCell Biotechnology Espana SL
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/593315-systemic-sclerosis-5
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Global Markets Direct Report Coverage 7
Systemic Sclerosis (Scleroderma) – Overview 8
Systemic Sclerosis (Scleroderma) – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Systemic Sclerosis (Scleroderma) – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 23
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Systemic Sclerosis (Scleroderma) – Companies Involved in Therapeutics Development 31
Allergan Plc 31
AnaMar AB 31
Angion Biomedica Corp 32
arGentis Pharmaceuticals LLC 32
Bayer AG 33
Biogen Inc 33
BLR Bio LLC 34
Boehringer Ingelheim GmbH 34
Bristol-Myers Squibb Company 35
Covis Pharmaceuticals Inc 35
CSL Ltd 36
Cumberland Pharmaceuticals Inc 36
- Hoffmann-La Roche Ltd 37
Fibrocell Science Inc 37
GenKyoTex SA 38
Gilead Sciences Inc 38
GlaxoSmithKline Plc 39
iBio Inc 39
Leadiant Biosciences Inc 40
MedImmune LLC 41
Patagonia Pharmaceuticals LLC 41
PDX Pharmaceuticals LLC 42
Peptinov SAS 42
ProMetic Life Sciences Inc 43
Ribomic Inc 43
Samumed LLC 44
Seattle Genetics Inc 45
Stemline Therapeutics Inc 45
Stratatech Corp 46
Vicore Pharma AB 46
viDA Therapeutics Inc 47
VivaCell Biotechnology Espana SL 47
Systemic Sclerosis (Scleroderma) – Drug Profiles 48
abatacept – Drug Profile 48
acALY-18 – Drug Profile 56
ambrisentan – Drug Profile 57
anabasum – Drug Profile 60
ANG-3070 – Drug Profile 68
ARG-201 – Drug Profile 69
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/593315-systemic-sclerosis-5
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218